OMCL Strangle Strategy
OMCL (Omnicell, Inc.), in the Healthcare sector, (Medical - Healthcare Information Services industry), listed on NASDAQ.
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001.
OMCL (Omnicell, Inc.) trades in the Healthcare sector, specifically Medical - Healthcare Information Services, with a market capitalization of approximately $1.96B, a trailing P/E of 95.76, a beta of 0.96 versus the broader market, a 52-week range of 26.85-55, average daily share volume of 597K, a public-listing history dating back to 2001, approximately 4K full-time employees. These structural characteristics shape how OMCL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.96 places OMCL roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. The trailing P/E of 95.76 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a strangle on OMCL?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current OMCL snapshot
As of May 15, 2026, spot at $43.08, ATM IV 44.50%, IV rank 5.56%, expected move 12.76%. The strangle on OMCL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on OMCL specifically: OMCL IV at 44.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a OMCL strangle, with a market-implied 1-standard-deviation move of approximately 12.76% (roughly $5.50 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated OMCL expiries trade a higher absolute premium for lower per-day decay. Position sizing on OMCL should anchor to the underlying notional of $43.08 per share and to the trader's directional view on OMCL stock.
OMCL strangle setup
The OMCL strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With OMCL near $43.08, the first option leg uses a $45.23 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed OMCL chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 OMCL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $45.23 | N/A |
| Buy 1 | Put | $40.93 | N/A |
OMCL strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
OMCL strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on OMCL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on OMCL
Strangles on OMCL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the OMCL chain.
OMCL thesis for this strangle
The market-implied 1-standard-deviation range for OMCL extends from approximately $37.58 on the downside to $48.58 on the upside. A OMCL long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current OMCL IV rank near 5.56% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on OMCL at 44.50%. As a Healthcare name, OMCL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to OMCL-specific events.
OMCL strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. OMCL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move OMCL alongside the broader basket even when OMCL-specific fundamentals are unchanged. Always rebuild the position from current OMCL chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on OMCL?
- A strangle on OMCL is the strangle strategy applied to OMCL (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With OMCL stock trading near $43.08, the strikes shown on this page are snapped to the nearest listed OMCL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are OMCL strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the OMCL strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 44.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a OMCL strangle?
- The breakeven for the OMCL strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current OMCL market-implied 1-standard-deviation expected move is approximately 12.76%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on OMCL?
- Strangles on OMCL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the OMCL chain.
- How does current OMCL implied volatility affect this strangle?
- OMCL ATM IV is at 44.50% with IV rank near 5.56%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.